default author photo

Alyson Kelvin

University of Saskatchewan - Vaccine and Infectious Disease Organization

SCHOLARLY PAPERS

2

DOWNLOADS

173

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Immunogenicity of a SARS-CoV-2 DNA Vaccine Formulated With the Fusion-Associated Small Transmembrane Protein Proteolipid Vehicle Delivery System

Number of pages: 49 Posted: 01 Nov 2022
Entos Pharmaceuticals, OncoSenX, Entos Pharmaceuticals, Entos Pharmaceuticals, University of Alberta - Department of Oncology, University of Alberta - Department of Oncology, Dalhousie University - Department of Microbiology & Immunology, Entos Pharmaceuticals, Entos Pharmaceuticals, Oisin Biotechnologies, Entos Pharmaceuticals, Entos Pharmaceuticals, Entos Pharmaceuticals, Entos Pharmaceuticals, University of Alberta - Department of Oncology, Entos Pharmaceuticals, Dalhousie University - Department of Microbiology & Immunology, Dalhousie University - Department of Microbiology & Immunology, Aegis Life, Entos Pharmaceuticals, Entos Pharmaceuticals, Aegis Life, Dalhousie University - Department of Microbiology & Immunology, Dalhousie University - Department of Microbiology & Immunology, Dalhousie University - Department of Microbiology & Immunology, University of Saskatchewan - Vaccine and Infectious Disease Organization, Aegis Life, University of Saskatchewan - Vaccine and Infectious Disease Organization, Dalhousie University - Department of Microbiology & Immunology and University of Alberta - Department of Oncology
Downloads 118 (608,822)

Abstract:

Loading...

CD8+ T cells, cytotoxic T lymphocytes, FAST protein, genetic adjuvants, neutralizing antibodies, plasmid DNA vaccine, proteolipid vehicle, PLV, SARS-CoV-2, Spike protein

2.

Efficacy of a Stable Broadly Protective Subunit Vaccine Platform Against Sars-Cov-2 Variants of Concern

Number of pages: 43 Posted: 18 Apr 2024
University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Vaccine Formulation Institute (VFI), University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Vaccine Formulation Institute (VFI), Vaccine Formulation Institute (VFI), University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Vaccine Formulation Institute (VFI), University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization and University of Saskatchewan - Vaccine and Infectious Disease Organization
Downloads 55 (1,010,164)

Abstract:

Loading...

SARS-CoV-2, subunit vaccine, broad protection, vaccine platform, emerging coronaviruses, Syrian hamsters